-
2023-503673-38-00
5
2019-05-24
Adults at high risk of cardiovascular events without prior MI or strok
-
2023-503898-38-00
5
2019-05-24
Atopic Dermatitis
-
2022-501971-24-00
5
2019-05-20
Adjuvant treatment of HCC
-
2023-509304-16-00
5
2019-05-16
Pulmonary arterial hypertension (PAH)
-
2022-502747-35-00
5
2019-02-18
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
-
2022-502936-38-00
5
2019-01-09
Moderate and Severe Atopic Dermatitis
-
2024-513513-12-00
5
2019-01-06
Cholangiocarcinoma
-
2023-508253-98-00
5
2018-10-05
Gastric or gastroesophageal junction (GEJ) adenocarcinoma
-
2024-514179-17-00
5
2018-10-02
Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cerv
-
2023-508472-11-00
5
2018-06-13
Patients with early breast cancer
-
2024-510634-41-00
4
2018-02-22
Recurrent, metastatic, or persistent Cervical Carcinoma
-
2024-513167-68-00
5
2017-11-29
endometrial cancer
-
2023-509595-42-00
5
2017-10-31
Gastric and gastroesophageal junction (GEJ) adenocarcinoma
-
2022-501251-81-00
5
2017-06-08
Renal cell carcinoma
-
2024-512934-14-00
5
2016-11-07
advanced or metastatic adenocarcinoma of the stomach or gastroesophage
-
2023-507294-18-00
5
2016-09-16
Metastatic renal cell carcinoma
-
2024-511235-10-00
5
2016-07-25
Generalized mantle cell Lymphoma
-
2024-512003-39-00
4
2016-07-18
Lung Cancer
-
2024-518022-33-00
5
2016-07-15
Advanced Stage of Hodgkin Lymphoma
-
2023-504034-22-00
5
2014-12-18
Chronic Lymphocytic Leukemia (CLL)
-
2022-501353-37-00
5
Reversal of anticoagulation effect in patients on a FXa inhibitor (api
-
2022-502040-13-00
4
High-risk Myelodysplastic neoplasia
-
2023-505735-13-01
9
Atopic dermatitis
-
2023-506487-13-00
5
Hormone receptor-positive, her2-negative advanced/metastatic breast ca